Resources

Support for you and appropriate patients with overt HE

The resources below include information that may help when prescribing XIFAXAN, insurance requirements, and videos about OHE. You’ll also find materials to share with patients with OHE. These resources may help you get patients on XIFAXAN and help them reach your goals for OHE management.

For your practice

Information on identifying patients at risk for OHE recurrence and how to act with guideline-based care.

A summary of dosing information for prescribing XIFAXAN.

Provides direction for submitting a PA for XIFAXAN when needed.

A standard form for a patientā€specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.

A Tier Exemption Request to reduce the cost-share of a medication. Follows submission of a PA or Utilization Management request.

Learn how QSA can support your patients and practice.

Get perspectives from your peers, tools, and educational material on diagnosis and treatment of OHE.

For your patients

A brief overview about managing OHE with XIFAXAN, including dosing and savings program details.

A handy tool to help patients and caregivers recognize the mental and physical symptoms of HE.

Learn about Extra Help/LIS program benefits. Identify the two ways patients can receive Extra Help/LIS benefits. Discover how you can help patients apply for Extra Help/LIS benefits.

Card Copay Card

Instant Savings Copay Card

The XIFAXAN Instant Savings Copay Card provides most eligible* commercially insured patients help with their monthly copays for XIFAXAN.

DOWNLOAD OR ACTIVATE NOW

*Patient is not eligible if he/she participates in, seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full-cash–paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com or call 1-866-XIFAXAN for full eligibility criteria, terms, and conditions.

HE, hepatic encephalopathy; LIS, Low-Income Subsidy

Video library

Take action! Explore the connection between the liver and brain in patients with chronic liver disease/cirrhosis at risk for developing hepatic encephalopathy.

Watch Dr. Jesudian discuss the AASLD Guidelines for managing overt HE with XIFAXAN.

Watch Dr. Poordad describe the Phase 3 clinical trial that assessed the efficacy of XIFAXAN in reducing the risk of recurrence for overt HE and HE-related hospitalizations.

See Dr. Flamm explain the reasons for screening patients with cirrhosis for hepatic encephalopathy.

View Dr. Flamm speaking about the importance of recognizing the symptoms of HE as a wide spectrum of neurological and psychiatric manifestations.

Hear Dr. Flamm describe in detail the symptoms of overt HE, from insomnia to full-fledged coma.

AASLD, American Association for the Study of Liver Diseases; HE, hepatic encephalopathy; LIS, low-income subsidy; OHE, overt hepatic encephalopathy; PA, prior authorization.

See More

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
See Less

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
    IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

XIF.0184.USA.23V3.0